Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.33 USD | -0.27% | +0.09% | -19.36% |
05-02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
05-01 | Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 150.21 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.62 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.36% | 81.46B | B- | ||
+29.68% | 681B | C+ | ||
+19.11% | 556B | B | ||
-4.35% | 361B | C+ | ||
+17.65% | 325B | B- | ||
+3.77% | 285B | C+ | ||
+13.49% | 235B | B+ | ||
+4.44% | 199B | B- | ||
-12.23% | 189B | A+ | ||
-3.79% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GILD Stock
- Ratings Gilead Sciences, Inc.